Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	3.64B
Revenue (ttm)	1.37B
Net Income (ttm)	416.83M
Shares Out	n/a
EPS (ttm)	0.54
PE Ratio	8.74
Forward PE	n/a
Dividend	0.21 (9.95%)
Ex-Dividend Date	Jul 2, 2024

Volume	131,300
Average Volume	183,190
Open	2.150
Previous Close	2.130
Day's Range	2.140 - 2.150
52-Week Range	1.950 - 2.660
Beta	n/a
RSI	50.86
Earnings Date	Mar 31, 2025

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2024, SGX:T14's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial numbers in CNY